gefapixant
Small moleculeexperimental
Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor. — Wikipedia
Clinical trial activity
28 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
7
Phase 2
20
Phase 3
7
Phase 4
0
Earliest trial started Aug 31, 2011 (NCT01432730)
Timeline
Indications
Mechanism of action
- P2X purinoceptor 3ANTAGONIST
P2RX3 antagonist
P2RX3 and P2RX2/3 trimers allosteric antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(C(C)C)c(Oc2cnc(N)nc2N)cc1S(N)(=O)=O- Mol. weight
- 353.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3716057 ↗
- WikipediaGefapixant ↗
- ChEMBLCHEMBL4594278 ↗
- ChEMBLCHEMBL3545041 ↗
Also known as
- af-219
- af-219
- gefapixant
- gefapixant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06542484 | N/A | Sep 6, 2024 | Merck, Nagoya City University |
| NCT05813223 | Early Phase 1 (Phase 1) | Dec 1, 2023 | Melbourne Health, Merck, Monash University, University of Melbourne |
| NCT05450601 | Phase 3 | Jul 13, 2022 | Hanmi Pharmaceutical |
| NCT04193176 | Phase 3 | Jan 24, 2020 | Merck |
| NCT04193202 | Phase 3 | Jan 14, 2020 | Merck |
| NCT04525885 | Phase 3 | May 17, 2019 | Merck |
| NCT03882801 | Phase 1 | Apr 10, 2019 | Merck |
| NCT03696108 | Phase 3 | Oct 31, 2018 | Merck |
| NCT03654326 | Phase 2 | Sep 11, 2018 | Merck |
| NCT03569033 | Phase 2 | Jul 4, 2018 | Merck |
| NCT03482713 | Phase 2 | Mar 16, 2018 | Merck |
| NCT03449147 | Phase 3 | Mar 15, 2018 | Merck |
| NCT03449134 | Phase 3 | Mar 14, 2018 | Merck |
| NCT03108924 | Phase 1 | Apr 14, 2017 | Merck |
| NCT02790840 | Phase 1 | May 16, 2016 | Afferent Pharmaceuticals, Celerion |
| NCT02612623 | Phase 2 | Dec 17, 2015 | Afferent Pharmaceuticals |
| NCT02612610 | Phase 2 | Dec 15, 2015 | Afferent Pharmaceuticals |
| NCT02476890 | Phase 2 | Oct 28, 2015 | Afferent Pharmaceuticals, University of Hull |
| NCT02502097 | Phase 2 | Aug 20, 2015 | Afferent Pharmaceuticals |
| NCT02477709 | Phase 2 | Jul 17, 2015 | Afferent Pharmaceuticals, American Health Research |
Showing 20 of 28 trials
Page 1 / 2
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Afferent Pharmaceuticals | For profit | 14 | 14 | 2 | 2011 |
| Merck | For profit | 13 | 11 | 4 | 2017 |
| Celerion | For profit | 3 | 0 | 1 | 2014 |
| University of Manchester | Academic/Hospital | 3 | 0 | 2 | 2011 |
| American Health Research | For profit | 1 | 0 | 1 | 2015 |
| Hanmi Pharmaceutical | For profit | 1 | 1 | 1 | 2022 |
| Melbourne Health | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Monash University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Nagoya City University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Hull | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Melbourne | Academic/Hospital | 1 | 1 | 1 | 2023 |
11 organizations
Page 1 / 1